Entera Bio Yönetim

Yönetim kriter kontrolleri 2/4

Entera Bio CEO'su Miranda Toledano, Jul2022 tarihinde atandı, in görev süresi 2.33 yıldır. in toplam yıllık tazminatı $ 950.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 35.6% maaş ve 64.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.3% ine doğrudan sahiptir ve bu hisseler $ 199.36K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 5.6 yıldır.

Anahtar bilgiler

Miranda Toledano

İcra Kurulu Başkanı

US$950.0k

Toplam tazminat

CEO maaş yüzdesi	35.6%
CEO görev süresi	2.3yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19

Entera Bio secures European patent for oral PTH formulations

Jun 17

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20

Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely

Dec 05

Entera Bio EPS misses by $0.22

Nov 19

CEO Tazminat Analizi

Miranda Toledano'un ücretlendirmesi Entera Bio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$950k	US$338k	-US$9m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$795k	US$231k	-US$13m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$14m
Dec 31 2021	US$82k	n/a	-US$12m

Tazminat ve Piyasa: Miranda 'nin toplam tazminatı ($USD 950.00K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 655.02K ).

Tazminat ve Kazançlar: Miranda şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Miranda Toledano (47 yo)

2.3yrs

Görev süresi

US$950,000

Tazminat

Ms. Miranda J. Toledano, M.B.A. serves as Chief Executive Officer of Entera Bio Ltd. since July 15, 2022. She serves as an Independent Director of Journey Medical Corporation since November 2021.She has b...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Miranda Toledano	CEO & Director	2.3yrs	US$950.00k	0.30% $ 199.4k
Dana Yaacov-Garbeli	Chief Financial Officer	2.3yrs	US$311.00k	0.16% $ 101.8k
Hillel Galitzer	Chief Operating Officer	10.8yrs	US$459.00k	0.094% $ 61.4k
Gregory Burshtein	Chief of Research & Development	less than a year	Veri yok	0.14% $ 90.0k

2.3yrs

Ortalama Görev Süresi

46.5yo

Ortalama Yaş

Deneyimli Yönetim: ENTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Miranda Toledano	CEO & Director	6.2yrs	US$950.00k	0.30% $ 199.4k
Steven Goldstein	Member of Clinical & Scientific Advisory Board	1.6yrs	Veri yok	Veri yok
Gerald Lieberman	Independent Chairman of the Board	10.6yrs	US$130.97k	0.80% $ 522.5k
Gerald Ostrov	Independent Director	5.8yrs	US$120.97k	0.11% $ 70.0k
Sofia Ish-Shalom	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yonatan Malca	Independent Director	13.8yrs	US$124.97k	0.11% $ 70.3k
Haya Taitel	Independent Director	1.4yrs	US$8.61k	0.16% $ 103.9k
Sean Ellis	Independent Director	5.4yrs	US$117.47k	0.35% $ 229.7k
Socrates Papapoulos	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
John Bilezikian	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Felicia Cosman	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
William Fraser	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

5.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ENTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Entera Bio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

Insufficient new directors

Recent updates

New minor risk - Share price stability

Entera Bio Ltd. Announces New Comparative Pharmacological Data for its Investigational Agent EB613 Vs. Forteo® Selected for Presentation at ASBMR

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Jul 31, 2024

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Shareholder dilution

Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Third quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 3Q 2022)

Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program

Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting

New minor risk - Share price stability

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Ltd., Annual General Meeting, Sep 13, 2023

First half 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1H 2022)

Entera Bio Ltd Adds Haya Taitel to its Board of Directors

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Consensus revenue estimates decrease by 97%, EPS upgraded

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

No longer forecast to breakeven

Entera Bio Ltd. Announces U.S. Food and Drug Administration Acceptance of Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Price target decreased by 11% to US$6.00

Entera Bio Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates increase by 59%

Price target increased to US$9.50

Insufficient new directors

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio Ltd. Announces Fda Agreement for A Single Phase 3 Clinical Trial to Support an NDA for Eb613 for the Treatment of Osteoporosis

Entera Bio Ltd. Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Price target increased to US$7.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Insufficient new directors

Entera Bio Ltd., Annual General Meeting, Sep 07, 2022

Entera Bio Ltd. Announces Executive Changes

Insufficient new directors

Entera Bio Ltd. Announces Departure of Dr. Phillip Schwartz, President of Research & Development to Pursue Outside Opportunities

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Entera Bio Ltd. Announces Appointment of Miranda Toledano as Chief Business Officer and Head of Corporate Strategy

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$6.75

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Entera Bio Ltd. to Report Fiscal Year 2021 Results on Mar 08, 2022

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Entera Bio Announces Successful EB613 End-Of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (Bone Mineral Density) as the Primary Endpoint

Consensus forecasts updated

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.086 loss per share (vs US$0.089 loss in 3Q 2020)

Price target decreased to US$11.00

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.17 loss in 2Q 2020)

Entera Bio Ltd. to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Forecast to breakeven in 2024